A Phase 4 interventional study of Memantine and Placebo in Alzheimer's Disease, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.
Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.
Among the 34 studies testing memantine in Alzheimer Disease, this one is the 6th largest by enrollment, is one of 4 that started in 2005, is one of 21 in phase 4, and was the 20th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–32
By country, each count listing its studies:
Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 21
First in 2003; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 277 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 90 across the 34 interventional studies. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
16 studies in Alzheimer Disease by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 16 studies in Alzheimer Disease by H. Lundbeck A/S, this one is the 9th largest by enrollment, is the only one that started in 2005, is one of 2 in phase 4, and was the 4th registered.
H. Lundbeck A/S’s Alzheimer Disease studies by the year they started, since 2003.
1 of the studies testing memantine in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05063851University of VirginiaThe Use of Memantine for Prevention of Alzheimer's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing memantine in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 16 in Alzheimer Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons. Previous studies have shown that memantine helps to treat the symptoms of Alzheimer's Disease (AD). In AD, the rate of brain tissue loss, or atrophy, is faster than in normal aging and this seems to go hand in hand with some of the symptoms of the disease. This suggests that memantine treatment in AD could provide both symptomatic improvement and neuro-protective effects. The purpose of this study was to show whether memantine, in addition to providing symptomatic benefits, can slow the rate of brain atrophy as assessed using magnetic resonance imaging (MRI) technology.
The primary objective of this study was to evaluate the effects of memantine on the rate of brain atrophy compared to placebo in patients with AD (moderate severity) over a 1-year period. This was a multinational, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study (20 mg memantine). The study also included secondary imaging, cognitive and behavioural measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Memantine
Drug: Placebo
10 mg tablets twice daily
Also known as: Ebixa®
Tablets twice daily
Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)
Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52)
Time frame: Baseline to 1 year
Changes in Total Hippocampal Volume (HCV)
Estimated mean changes in total HCV
Time frame: Baseline to 1 year
Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score
Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment
Time frame: Baseline to 1 year
Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score
Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state
Time frame: Baseline to 1 year
The patients were recruited from each investigator's outpatient clinic.
| Milestone | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| Started | 133 | 144 |
| Completed | 103 | 114 |
| Not completed | 30 | 30 |
| Withdrew: Adverse event | 15 | 12 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Protocol violation | 2 | 5 |
| Withdrew: Withdrawal by subject | 4 | 6 |
| Withdrew: Non-compliance | 4 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative or other reason(s) | 4 | 3 |
Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52)
| mL/year | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI) | 15.24 ± 0.97 | 15.32 ± 0.91 |
Estimated mean changes in total HCV
| mm^3/year | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| Changes in Total Hippocampal Volume (HCV) | -218 ± 182 | -220 ± 171 |
Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment
| Scale scores | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score | 0.78 ± 0.71 | -0.90 ± 0.69 |
Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state
| Scale scores | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score | -0.50 ± 0.45 | -0.74 ± 0.44 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine 10 mg Tablets Twice Daily | — | 17/133 (12.8%) | 46/133 (34.6%) |
| Placebo Tablets Twice Daily | — | 20/144 (13.9%) | 36/144 (25%) |
| Event | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| FallInjury, poisoning and procedural complications | 4/133 | 8/144 |
| Atrial fibrillationCardiac disorders | 3/133 | 0/144 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/133 | 3/144 |
| HypotensionVascular disorders | 0/133 | 2/144 |
| Abnormal behaviourPsychiatric disorders | 1/133 | 0/144 |
| AgitationPsychiatric disorders | 1/133 | 1/144 |
| AnaemiaBlood and lymphatic system disorders | 1/133 | 0/144 |
| Ankle fractureInjury, poisoning and procedural complications | 1/133 | 0/144 |
| Balance disorderNervous system disorders | 1/133 | 0/144 |
| Cardiac failureCardiac disorders | 1/133 | 0/144 |
| Event | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily |
|---|---|---|
| DizzinessNervous system disorders | 11/133 | 4/144 |
| DiarrhoeaGastrointestinal disorders | 4/133 | 10/144 |
| HeadacheNervous system disorders | 9/133 | 7/144 |
| FallInjury, poisoning and procedural complications | 8/133 | 9/144 |
| AgitationPsychiatric disorders | 7/133 | 1/144 |
| Urinary tract infectionInfections and infestations | 7/133 | 5/144 |
| Age Continuous(years) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 73.7 ± 8.8 | 74.4 ± 7.7 | 74.1 ± 8.3 |
| Sex: Female, Male(Participants) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Female | 83 | 75 | 158 |
| Male | 50 | 69 | 119 |
| Controlled Oral Word Association Test (COWAT): Baseline Efficacy Scores(Number of words) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 19.7 ± 10.3 | 19.2 ± 8.8 | 19.4 ± 9.6 |
| Category Fluency Test (CFT): Baseline Efficacy Scores(Number of words) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 13.5 ± 5.8 | 13.3 ± 5.9 | 13.4 ± 5.9 |
| ADAS-cog-Orientation Test (ADAS-cog-OT): Baseline Efficacy Scores(Points) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 4.2 ± 1.6 | 4.0 ± 1.7 | 4.1 ± 1.7 |
| Stroop Interference Test - Incongruent (SIT-I): Baseline Efficacy Scores(Seconds) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 170.3 ± 60.4 | 176.4 ± 56.7 | 173.4 ± 58.5 |
| Stroop Interference Test - Congruent (SIT-C): Baseline Efficacy Scores(Seconds) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 70.5 ± 49.1 | 68.8 ± 41.7 | 69.6 ± 45.4 |
| Mini Mental State Examination (MMSE): Baseline Efficacy Scores(Points) | Memantine 10 mg Tablets Twice Daily | Placebo Tablets Twice Daily | Total |
|---|---|---|---|
| Mean | 16.9 ± 2.4 | 17.0 ± 2.4 | 16.9 ± 2.4 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Sep 2005, a primary completion of Feb 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine